Replies to post #149079 on Cytodyn Inc (CYDY)

[CTMedic]

Kgro,

Leronlimab will be judged on the results of clinical trials. I have posted repeatedly that cd10 demonstrated efficacy, albeit in the mild/moderate population.

CD12 is complete, results in the hands of the FDA, MHRA and Health Canada.

You stated

I have shown many times here the statistical reasons (across >100 worldwide research studies) explaining why Leronlimab is a statistical failure, and the business signs that Cytodyn is a stock market fraud.

.

You have CLAIMED that your statistical analysis demonstrates leronlimab is a failure. However, these analyses have been based on your supposition that CD12 excluded critical patients (criteria #3 that limits inclusion to patients with PAO2 /FIO2 >150 with PEEP<20cm H2O).

Severe ARDS is not the only criteria for severe and critical Covid.

The CD12 results will be judged by the statistical analysis of FDA, Health Canada and MHRA.

We’re the results poor (easily determined in a few minutes or hours), there would be no ongoing discussions with these agencies, yet the meeting continue in private.

Cytodyn remains a pre-revenue biotech with excellent prospects. Thus increasing institutional investment and many fold increase in stock price from late 2019.

Nonetheless,I do agree with one point you have made.

Everything is consistent and aligned.

IMO the result of that consistency and alignment will be approval of leronlimab for severe Covid in multiple countries.

We are five days into the 2-3 period indicated in the Feb 22 press release.

Patience.

GLTU/A

[moneycrew]

I guess that the people who bought 322K shares at TEFQX must be amateurs. I'm wondering if they fall under the selective disclosure rule of the SEC and therefore invested in CYDY. They have analysts in house, i'm sure they know what they are doing. We're still up over 300 percent for the year no?

[Dieselpro]

You also told us they were looking at mortality out to February 31